GIUGNO 2026
PBC
Prof.ssa Cristina Rigamonti
Dipartimento Medicina Traslazionale, Università Piemonte Orientale, AOU Maggiore della Carità di Novara, Novara, Italia
Long-term improvements in lipid profiles with elafibranor treatment, and favourable safety with concomitant statin use, in patients with primary biliary cholangitis during the open-label extension of the phase III ELATIVE® trial
Bone mineral density is stable in patients with primary biliary cholangitis receiving up to 3.5 years of elafibranor treatment
Long-term treatment with elafibranor improves markers of immune response and inflammation in primary biliary cholangitis
Improvements in fatigue in patients with primary biliary cholangitis treated with elafibranor: patient-reported outcome measurement information system fatigue short form 7a (PFSF 7a) data from the phase III ELATIVE® trial
Prof. Andrea Galli
Azienda Ospedaliera Universitaria Careggi, Università degli Studi di Firenze, Firenze, Italia
Prof. Marco Carbone
Università Milano-Bicocca, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italia
Real-world validation of elafibranor in UDCA non-responders previously treated with OCA or fibrates — results from the ELEVATE-PBC study
Real-world experience with Elafibranor in patients with primary biliary cholangitis previously treated with Obeticholic acid: an italian multicenter observational study
Prof.ssa Vincenza Calvaruso
Università degli Studi di Palermo, Palermo, Italia
Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1× to 1.67× the upper limit of normal
Demographic and clinical characteristics of United States real-world patients with primary biliary cholangitis and alkaline phosphatase between 1 and 1.67 vs ≥ 1.67 × upper limit of normal despite ursodeoxycholic acid treatment
NOVEMBRE 2025
ATRESIA-BILIARE
Dott. Emanuele Nicastro
ASST Papa Giovanni XXIII, Bergamo, Italia
ODEVIXIBAT RAPIDLY REDUCES PRURITUS AND SERUM BILE ACIDS IN CHILDREN WITH BILIARY ATRESIA AND CHRONIC CHOLESTASIS FOLLOWING KASAI PORTOENTEROSTOMY
BOLD AND BOLD-EXT, THE FIRST GLOBAL PHASE III CLINICAL PROGRAM TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF ODEVIXIBAT IN INFANTS WITH BILIARY ATRESIA AFTER KASAI HEPATOPORTOENTEROSTOMY – STUDY DESIGN AND CURRENT STATUS
PBC
Prof. Marco Carbone
Università di Milano-Bicocca, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italia
OVERVIEW SESSIONE “GLOBAL CONSENSUS PRIMARY BILIARY CHOLANGITIS (PBC) ENDPOINTS - EASL/ AASLD JOINT PROGRAM”
Prof. Vincenzo Ronca
Humanitas University, Pieve Emanuele (MI), Italia
TREATMENT WITH ELAFIBRANOR LEADS TO STABILIZATION OF PRO-C3, A MARKER OF FIBROSIS, IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
THE EFFICACY OF ELAFIBRANOR IS NOT AFFECTED BY BODY MASS INDEX IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
LONG-TERM TREATMENT WITH ELAFIBRANOR LEADS TO A BIOCHEMICAL AND SYMPTOMATIC IMPROVEMENTS FOR AT LEAST 3 YEARS IN PATIENTS WITH PRIMARY BLIARY CHOLANGITIS
Dott. Alessio Gerussi
Università degli Studi di Milano-Bicocca, Monza (MB), Italia
CHANGES IN FATIGUE AND PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH ELAFIBRANOR ARE LARGELY INDEPENDENT FROM IMPROVEMENTS IN SERUM BIOMARKERS
IDENTIFICATION OF BST2, IL18R1, IL4R, AND KCNJ11 AS ASSOCIATED WITH PRURITUS RESPONSE TO ELAFIBRANOR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: PROTEOMIC RESULTS: FROM THE ELATIVE® TRIAL
ELAFIBRANOR-ASSOCIATED CHANGES IN PROTEINS LINKED TO MITOCHONDRIAL FUNCTION CORRELATE WITH FATIGUE IMPROVEMENT; PROTEOMIC RESULTS FROM ELATIVE TRIAL
PFIC
Dott. Angelo Di Giorgio
Centro di Riferimento Oncologico, Aviano (PN), Italia
PREDICTING RESPONSE TO ODEVIXIBAT TREATMENT AND COMPARISON BETWEEN CLASSICAL TYPES AND RARER FORMS OF CHILDREN WITH PFIC
Dott. Mauro Viganò
ASST Papa Giovanni XXIII, Bergamo, Italia
THE ROLE OF CHOLESTATIC GENETIC TESTING IN THE EVALAUTION OF PATIENTS WITH UNEXPLAINED CHOLESTASIS
CHARACTERIZATION OF A COHORT OF PATIENTS WITH LATER-ONSET PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) FROM TWO US HEALTH SYSTEMS IDENTIFIED LEVERAGING NATURAL LANGUAGE PROCESSING (NLP)
PSC
Dott.ssa Laura Cristoferi
Fondazione IRCCS San Gerardo Dei Tintori, Monza (MB), Italia
LONG-TERM DATA OF ELAFIBRANOR IN PRIMARY SCLEROSING CHOLANGITIS: INTERIM SAFETY AND EFFICACY DATA FROM THE ONGOING OPEN LABEL EXTENSION OF THE ELMWOOD PHASE II TRIAL
NOVEMBRE 2023
PBC
Prof. Umberto Vespasiani
Università Campus Bio-Medico di Roma,
Roma, Italia
PREDICTION OF BIOCHEMICAL RESPONSE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH OBETICHOLIC ACID: DERIVATION AND EXTERNAL VALIDATION OF THE OCA RESPONSE SCORE (ORS)
Prof. Alessio Aghemo
Prof. Alessio Aghemo Humanitas Research, Humanitas University,
Pieve Emanuele (MI), Italia
PREVALENCE AND TREATMENT OF PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): RESULTS FROM THE GERMAN PBC REGISTRY
HYPERLIPIDEMIA, ATHEROSCLEROSIS AND HEPATOSTEATOSIS IN PRIMARY BILIARY CHOLANGITIS: WHAT IS THE RISK?
INCREASED RISK OF OSTEOPOROTIC FRACTURE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
IMPACT OF TYPE 2 DIABETES MELLITUS ON LIVER FIBROSIS AND HEPATIC STEATOSIS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: A LONGITUDINAL STUDY
Prof.ssa Nora Cazzagon
Università di Padova, Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche,
Padova, Italia
UNDERSTANDING THE EXPERIENCE OF PEOPLE LIVING WITH PRIMARY BILIARY CHOLANGITIS: DEVELOPMENT OF AN EXPERIENCE MAP
DEVELOPMENT OF A PRIMARY BILIARY CHOLANGITIS (PBC)-SPECIFIC VERSION OF CHRONIC LIVER DISEASE QUESTIONNAIRE: CLDQ-PBC
IDENTIFYING DRIVERS OF PATIENT (PT) PREFERENCE IN THE TREATMENT OF PRURITUS IN PRIMARY BILIARY CHOLANGITIS (PBC)
Dott.ssa Alessandra Mangia
Dott.ssa Alessandra Mangia IRCCS Ospedale Casa Sollievo della Sofferenza, Opera di Padre Pio,
San Giovanni Rotondo (FG), Italia
EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE RESPONSE TRIAL: A PHASE 3 INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED STUDY
Prof.ssa Vincenza Calvaruso
Università degli Studi di Palermo,
Palermo, Italia
REAL-WORLD EVIDENCE, CLINICAL CHARACTERISTICS, & DISEASE PROGRESSION INSIGHTS FROM A GLOBAL COHORT OF PRIMARY BILIARY CHOLANGITIS PATIENTS DIAGNOSED BETWEEN 2015 AND 2023
REAL-WORLD EXPERIENCE WITH FIBRATES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
EFFECTIVENESS AND SAFETY OF SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS (PBC): A PROSPECTIVE MULTICENTER REAL-WORLD COHORT
Prof Pietro Invernizzi
Centro per le Malattie Autoimmuni del Fegato (MAF), IRCCS San Gerardo dei Tintori,
Monza (MB), Italia
EFFICACY AND SAFETY OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS: RESULTS FROM THE ELATIVE™ DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
PFIC-ALGS
Prof. Marco Carbone
Università degli Studi di Milano-Bicocca,
Milano, Italia
ODEVIXIBAT EFFICACY AND SAFETY ACROSS PATIENT SUBGROUPS: AN EVALUATION OF POOLED DATA FROM THE PEDFIC 1 AND PEDFIC 2 TRIAL
INDIVIDUAL PRURITUS AND BILE ACID RESPONSES OVER TIME WITH ODEVIXIBAT TREATMENT: POOLED DATA FROM THE PHASE 3 ASSERT AND ASSERT-EXT STUDIES IN PATIENTS WITH ALAGILLE SYNDROME
OUTCOMES WITH ODEVIXIBAT TREATMENT IN PATIENTS WITH ALAGILLE SYNDROME: ANALYSIS OF PRURITUS RESPONDERS FROM THE PHASE 3 ASSERT STUDY
Prof.ssa Ana Lleo
Humanitas University,
Pieve Emanuele (MI), Italia
LONG-TERM MAINTENANCE OF RESPONSE AND IMPROVED LIVER HEALTH WITH MARALIXIBAT IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC): 2-YEAR DATA FROM THE MARCH-ON STUDY
IMPROVEMENTS IN PRURITUS WITH MARALIXIBAT ARE ASSOCIATED WITH IMPROVED QUALITY OF LIFE FOR PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM THE MARCH-PFIC TRIAL
MARALIXIBAT LEADS TO SIGNIFICANT IMPROVEMENT IN CHOLESTATIC PRURITUS FOR CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO TJP2 OR MYO5B DEFICIENCY: DATA FROM THE MARCH-PFIC TRIAL